Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras ...

NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for ...

In 2001, they teamed up with colleagues at The Wellcome Trust Sanger Institute to investigate BRAF in more detail. They found that BRAF mutations are present in a number of cancers, including ...

FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

(B) Incidence of BRAF mutations and co-occurring mutations in any RAS gene. (C) Incidence of co-occurring KRAS and PIK3CA mutations.

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

colorectal (colon) cancer; epidermal growth factor receptor (EGFR); RAS; liquid biopsy; rechallenge; cetuximab; RAS; ...